<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02371499</url>
  </required_header>
  <id_info>
    <org_study_id>PROBE-IBS/14</org_study_id>
    <nct_id>NCT02371499</nct_id>
  </id_info>
  <brief_title>Effect of Lactobacillus Casei DG (Enterolactis Plus®) in Patient With Irritable Bowel Syndrome: a Pilot Study</brief_title>
  <official_title>Effect of Lactobacillus Casei dg (Enterolactis Plus®) in Patient With Irritable Bowel Syndrome: Multicenter, Randomized, Double-blind, Cross-over, Placebo Controlled, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOFAR S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SOFAR S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to collect data for the assessment of the Lactobacillus casei DG
      (Enterolactis plus®) effect on overall abdominal pain/discomfort, symptoms and gut microbiota
      composition in patients with Irritable Bowel Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to collect data for the assessment of the Lactobacillus casei DG
      (Enterolactis plus®) effect on overall abdominal pain/discomfort, symptoms and gut microbiota
      composition in patients with Irritable Bowel Syndrome. The investigators suppose that, due to
      the immunomodulatory action of probiotics, overall abdominal pain/discomfort and symptoms
      will improve, fecal Immunoglobulin A levels will change, pro-inflammatory cytokine levels
      will decrease and the production of regulatory cytokines as Interleukin 10 will improve
      following consumption of Lactobacillus casei DG (Enterolactis plus®).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abdominal pain/discomfort as measured by 11-point Numerical Rating Scale</measure>
    <time_frame>1 day</time_frame>
    <description>evaluation performed using a daily 11-point Numerical Rating Scale scale from &quot;0&quot; (none) to &quot;10&quot; (very severe) - (responders are defined as patients with ≥ 30% reduction in the weekly mean abdominal pain and/or discomfort score, versus mean value of run-in period, in at least 2 weeks out of the 4 weeks of the treatment period)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Irritable Bowel Syndrome degree-of-relief as measured by 7-point balanced ordinal scale</measure>
    <time_frame>1 week</time_frame>
    <description>evaluation performed using weekly 7-point balanced ordinal scale, where &quot;1&quot;=&quot;completely relieved&quot;, &quot;4&quot;=&quot;unchanged&quot; and &quot;7&quot;=&quot;as bad as I can imagine&quot; - (responders are defined as patients reporting &quot;completely relieved&quot;=score 1 or &quot;considerably relieved&quot;=score 2 in at least 2 weeks out of the 4 weeks of the treatment period)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stool frequency and consistency as assessed by Bristol Scale</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiota of fecal sample as characterized by Ion Torrent Personal Genome Machine sequencing of 16S ribosomal RNA-based amplicons</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall satisfaction with treatment as measured by Visual Analogue Scale</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life as measured by Short-Form 12 Items Health Survey</measure>
    <time_frame>4 weeks</time_frame>
    <description>evaluation performed using the validated Short-Form 12 Items Health Survey (SF-12) on a scale of 0 to 100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anxiety and Depression as assessed by Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>4 weeks</time_frame>
    <description>evaluation performed using Hospital Anxiety and Depression Scale (HADS): seven items each for anxiety and depression, with a 4-point Likert scale (0-3) for each item providing a minimum score of 0 and a maximum score of 21 on each sub-scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Consumption of rescue medication</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Secretory Immunoglobulin A and cytokines levels in fecal samples as measured by ELISA test.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>1st Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Lactobacillus casei DG (Enterolactis plus®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2nd Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with equivalent product without bacteria (Enterolactis placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus casei DG</intervention_name>
    <description>the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks</description>
    <arm_group_label>1st Arm</arm_group_label>
    <other_name>Enterolactis plus®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks</description>
    <arm_group_label>2nd Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years and ≤ 65 years.

          -  A positive diagnosis of Irritable Bowel Syndrome regardless of bowel habit (both males
             and females), according to Rome III criteria.

          -  Negative outcome of barium enema or left colonoscopy within the previous two years.

          -  Negative relevant additional screening or consultation whenever appropriate.

          -  Ability of conforming to the study protocol.

        Exclusion Criteria:

          -  Presence of any relevant organic, systemic or metabolic disease (particularly
             significant history of cardiac, renal, neurological, psychiatric, oncology,
             endocrinology, metabolic or hepatic disease), or abnormal laboratory values that will
             be deemed clinically significant on the basis of predefined values.

          -  Ascertained intestinal organic diseases, including ascertained celiac disease or
             inflammatory bowel diseases (Crohn's disease, ulcerative colitis, diverticular
             disease, infectious colitis, ischemic colitis, microscopic colitis).

          -  Previous major abdominal surgeries.

          -  Active malignancy of any type, or history of a malignancy (patients with a history of
             other malignancies that have been surgically removed and who have no evidence of
             recurrence for at least five years before study enrolment are also acceptable).

          -  Untreated food intolerance such as ascertained or suspected lactose intolerance, as
             defined by anamnestic evaluation or, if appropriate, lactose breath test.

          -  Assumption of probiotics or topic and/or systemic antibiotic therapy during the last
             month.

          -  Systematical/frequent assumption of contact laxatives.

          -  Females of childbearing potential, in the absence of effective contraceptive methods.

          -  Pregnant women.

          -  Inability to conform with protocol.

          -  Treatment with any investigational drug within the previous 30 days.

          -  Recent history or suspicion of alcohol abuse or drug addiction.

          -  Previous participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giorvanni Barbara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico S. Orsola-Malpighi - Azienda Ospedaliero-Universitaria di Bologna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico S.Donato</name>
      <address>
        <city>San Donato</city>
        <state>Milano</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ULSS 1</name>
      <address>
        <city>Belluno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Gastroenterologia Universitaria</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006 Apr;130(5):1480-91. Review. Erratum in: Gastroenterology. 2006 Aug;131(2):688.</citation>
    <PMID>16678561</PMID>
  </reference>
  <reference>
    <citation>Barbara G, Stanghellini V. Biomarkers in IBS: when will they replace symptoms for diagnosis and management? Gut. 2009 Dec;58(12):1571-5. doi: 10.1136/gut.2008.169672. Review.</citation>
    <PMID>19923339</PMID>
  </reference>
  <reference>
    <citation>Cremon C, Carini G, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G. Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon? Expert Rev Mol Diagn. 2010 May;10(4):389-93. doi: 10.1586/erm.10.33.</citation>
    <PMID>20465494</PMID>
  </reference>
  <reference>
    <citation>Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013 Jan;62(1):159-76. doi: 10.1136/gutjnl-2012-302167. Epub 2012 Jun 22.</citation>
    <PMID>22730468</PMID>
  </reference>
  <reference>
    <citation>Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011 Nov;141(5):1792-801. doi: 10.1053/j.gastro.2011.07.043. Epub 2011 Aug 5.</citation>
    <PMID>21820992</PMID>
  </reference>
  <reference>
    <citation>Jeffery IB, O'Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012 Jul;61(7):997-1006. doi: 10.1136/gutjnl-2011-301501. Epub 2011 Dec 16.</citation>
    <PMID>22180058</PMID>
  </reference>
  <reference>
    <citation>Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010 Mar;59(3):325-32. doi: 10.1136/gut.2008.167270. Epub 2008 Dec 17. Review.</citation>
    <PMID>19091823</PMID>
  </reference>
  <reference>
    <citation>Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001 Sep;121(3):580-91.</citation>
    <PMID>11522742</PMID>
  </reference>
  <reference>
    <citation>Eun CS, Kim YS, Han DS, Choi JH, Lee AR, Park YK. Lactobacillus casei prevents impaired barrier function in intestinal epithelial cells. APMIS. 2011 Jan;119(1):49-56. doi: 10.1111/j.1600-0463.2010.02691.x. Epub 2010 Oct 25.</citation>
    <PMID>21143526</PMID>
  </reference>
  <reference>
    <citation>Corinaldesi R, Stanghellini V, Cremon C, Gargano L, Cogliandro RF, De Giorgio R, Bartesaghi G, Canovi B, Barbara G. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther. 2009 Aug;30(3):245-52. doi: 10.1111/j.1365-2036.2009.04041.x. Epub 2009 May 12.</citation>
    <PMID>19438846</PMID>
  </reference>
  <reference>
    <citation>Quigley EM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, Diaz C, Shiff SJ, Currie MG, Johnston JM. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther. 2013 Jan;37(1):49-61. doi: 10.1111/apt.12123. Epub 2012 Nov 1.</citation>
    <PMID>23116208</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2015</study_first_submitted>
  <study_first_submitted_qc>February 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2015</study_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Lactobacillus casei dg</keyword>
  <keyword>microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

